Citations

Clear

9383 citation(s) found for "Thomas, PS".

Degree of Variability in Performance on Breast Cancer Quality Indicators: Findings From the Florida Initiative for Quality Cancer Care
Gray, Jhanelle E. , Laronga, Christine , Siegel, Erin M. , Lee, Ji‐Hyun , Fulp, William J. , Fletcher, Michelle , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George , Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Shibata, David , Malafa, Mokenge P. , Jacobsen, Paul B. , Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | July 15, 2011 | Volume: 7 | Issue: 4 | Pages: 247-251

10.1200/jop.2010.000174 | PMID 22043190 Get It

The Florida Initiative for Quality Cancer Care has identified how multiple aspects of breast cancer care can be improved.
Conformationally Constrained Peptides from CD2 To Modulate Protein–Protein Interactions between CD2 and CD58
Gokhale, Ameya, Weldeghiorghis, Thomas K. , Taneja, Veena , Satyanarayanajois, Seetharama D., Taneja, Veena

Mayo Clinic

Journal of Medicinal Chemistry | July 14, 2011 | Volume: 54 | Issue: 15 | Pages: 5307-5319

10.1021/jm200004e | PMID 21755948 Get It

Success of Ablation for Atrial Fibrillation in Isolated Left Ventricular Diastolic Dysfunction
Cha, Yong-Mei , Wokhlu, Anita , Asirvatham, Samuel J. , Shen, Win‐Kuang , Friedman, Paul A. , Munger, Thomas M. , Oh, Jae K. , Monahan, Kristi H. , Haroldson, Janis M., Hodge, David O. , Herges, Regina M., Hammill, Stephen C., Packer, Douglas L. , Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 12, 2011 | Volume: 4 | Issue: 5 | Pages: 724-732

10.1161/circep.110.960690 | PMID 21747059 Get It

Background— The efficacy of radiofrequency ablation for atrial fibrillation (AF) in patients with left ventricular (LV) systolic dysfunction and isolated diastolic dysfunction is uncertain. Methods and Results— A prospective cohort of patients with normal and abnormal LV function underwent ablation for antiarrhythmic drug (AAD)-refractory AF. Three groups were compared: 111 patients with systolic dysfunction, defined as LV ejection fraction (LVEF) ≤40%; 157 patients with isolated diastolic dysfunction but preserved LVEF ≥50%; and 100 patients with normal LV function. The primary end point was AAD-free AF elimination at 1 year after ablation. This end point was achieved in 62% of patients with systolic dysfunction, 75% of those with diastolic dysfunction, and 84% of controls ( P =0.007). AF control on or off AADs was achieved in 76% of patients with systolic dysfunction, 85% of those with diastolic dysfunction, and 89% of controls ( P =0.08). In the systolic dysfunction group, 49% experienced an increase in LVEF by ≥5% after ablation, of which 64% achieved normal LVEF. In the diastolic dysfunction group, 30% of patients demonstrated at least 1 grade improvement in diastolic dysfunction. Multivariable analysis demonstrated an increased relative risk of arrhythmia recurrence of 1.8 (95% CI, 1.1 to 3.1; P =0.02) in systolic dysfunction and 1.7 (1.0 to 2.7; P =0.04) in isolated diastolic dysfunction compared with normal function. Conclusions— Although an ablative approach for AF in patients with systolic or diastolic dysfunction is associated with an increased long-term recurrence risk, there is potential for substantial quality-of-life improvement and LV functional benefit.
Natural History of Headache after Traumatic Brain Injury
Hoffman, Jeanne M. , Lucas, Sylvia , Dikmen, Sureyya, Braden, Cynthia, Brown, Allen W. , Brunner, Robert, Diaz‐Arrastia, Ramon , Watanabe, Thomas K. , Bell, Kathleen , Walker, William C. , Bell, Kathleen , Diaz-Arrastia, Ramon

Mayo Clinic

Journal of Neurotrauma | July 6, 2011 | Volume: 28 | Issue: 9 | Pages: 1719-1725

10.1089/neu.2011.1914 | PMID 21732765 Get It

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
Micallef, Ivana N. , Ansell, Stephen M. , Link, Brian K. , Inwards, David J. , Porrata, Luis F. , Johnston, Patrick B. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Allmer, Cristine, Maurer, Matthew J. , Weiner, George J. , Hohl, R.J., Kurtin, Paul J. , Ding, Husheng, Loegering, David A., Schneider, Paula A., Peterson, Kevin, Witzig, Thomas E. , Tang, Hui Jun , Colgan, Joseph P. , Markovic, Svetomir N. , Gupta, Mamta , Habermann, Thomas M. , Kaufmann, Scott H. , Maurer, Matthew , Link, Brian K , Weiner, George

Mayo Clinic

Blood | July 4, 2011 | Volume: 118 | Issue: 18 | Pages: 4882-4889

10.1182/blood-2011-02-334904 | PMID 21725056 Get It

AbstractA phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressive B-cell, indolent B-cell, and T-cell and Hodgkin lymphoma (HL/T) groups, the response rates were 17% (7/42), 7% (1/15), and 31% (11/36), respectively. Of the 19 responders, 7 were diffuse large B-cell non-Hodgkin lymphoma (NHL), 7 T-cell NHL, 1 follicular grade 2, and 4 HL. The median response duration for the 19 responders was 7.2 months (mean, 15.8 months; range, 1.8-62), and 5 patients in the HL/T group are still receiving treatment at 29-64+ months. The grade 3/4 toxicities observed were fatigue and reversible myelosuppression. Correlative studies suggest that Bim and Bcl-2 should be examined as potential predictors of response in future studies. These results indicate that tipifarnib has activity in lymphoma, particularly in heavily pretreated HL/T types, with little activity in follicular NHL. In view of its excellent toxicity profile and novel mechanism of action, further studies in combination with other agents appear warranted. This trial is registered at www.clinicaltrials.gov as #NCT00082888.
Radiation Dose Levels for Interventional CT Procedures
Christner, Jodie A., Carlson, Stephanie K., Jacobsen, Megan C. , Vrieze, Thomas J., Atwell, Thomas D. , Leng, Shuai , McCollough, Cynthia H.

Mayo Clinic

American Journal of Roentgenology | July 1, 2011 | Volume: 197 | Issue: 1 | Pages: W97-W103

10.2214/ajr.10.5057 | PMID 21701002 Get It

Soluble IL-2Rα facilitates IL-2–mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma
Yang, Zhi‐Zhang, Grote, Deanna M., Ziesmer, Steven C., Novak, Anne J. , Ansell, Stephen M. , Manske, Michelle K. , Witzig, Thomas E.

Mayo Clinic

Blood | July 1, 2011 | Volume: 118 | Issue: 10 | Pages: 2809-2820

10.1182/blood-2011-03-340885 | PMID 21719603 Get It

AbstractElevated serum levels of the soluble form of IL-2 receptor α (sIL-2Rα) have been correlated with a poor prognosis in a variety of different types of cancers. However, its biologic relevance remains unclear and controversial. In patients with follicular B-cell non-Hodgkin lymphoma (FL), we observed that serum sIL-2Rα levels were elevated compared with controls and that elevated sIL-2Rα levels before treatment were associated with a poor outcome. To explore the mechanism by which sIL-2Rα may contribute to a poor prognosis in FL, we determined the effects of sIL-2Rα on IL-2 signaling and found that the sIL-2Rα–IL-2 complex promoted T-cell differentiation toward to inhibitory Treg cells rather than TH1 or TH17 cells. Shed by activated T cells that express membrane-bound IL-2Rα, sIL-2Rα further enhanced IL-2–mediated phosphorylation of Stat5 thereby significantly up-regulating Foxp3 expression in CD4+ T cells. We found that CD4+ T cells treated with either IL-2 or sIL-2Rα–IL-2 complex, but not with sIL-2Rα alone, inhibited the function of CD8+ T cells. Taken together, these results indicate that sIL-2Rα actually plays an active biologic role in FL by binding IL-2 and promoting IL-2 signaling rather than depleting IL-2 and blocking its function.
Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes
Jackson, Graham, Jones, T. Hugh , Matsumoto, Alvin M. , Nehra, Ajay, Perelman, Michael A. , Traish, A., Zitzmann, Michael , Cunningham, Glenn R. , Wang, Christina , Swerdloff, Ronald S.

Mayo Clinic

Diabetes Care | June 28, 2011 | Volume: 34 | Issue: 7 | Pages: 1669-1675

10.2337/dc10-2339 | PMID 21709300 Get It

Correlates of quitting the Paced Auditory Serial Addition Test in cognitively normal older adults participating in a study of normal cognitive aging
Locke, Dona E.C. , Stonnington, Cynthia M. , Thomas, Michael L. , Caselli, Richard J. , Locke, Dona E C

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | June 27, 2011 | Volume: 33 | Issue: 8 | Pages: 937-943

10.1080/13803395.2011.578571 | PMID 21950515 Get It

Doppler evaluation of results of percutaneous aortic balloon valvuloplasty in calcific aortic stenosis.
Nishimura, R A, Holmes, David R. , Reeder, Guy S., Orszulak, Thomas A., Bresnahan, John F., Ilstrup, D M, Tajik, A. Jamil

Mayo Clinic

Circulation | June 17, 2011 | Volume: 78 | Issue: 4 | Pages: 791-799

10.1161/01.cir.78.4.791 | PMID 3168188 Get It

To evaluate the short-term results of percutaneous aortic balloon valvuloplasty, 55 consecutive elderly patients with symptomatic, severe aortic stenosis who were at high risk for surgical intervention underwent the procedure, with follow-up by clinical evaluation and Doppler echocardiography. Over a mean follow-up of 6.2 months, there were three early deaths (less than 30 days) and eight late deaths. Nine patients underwent subsequent aortic valve surgery, and four had repeat balloon valvuloplasty. Doppler echocardiography revealed a reduction in aortic valve mean gradient from 48 +/- 18 to 33 +/- 12 mm Hg after the procedure (p less than 0.0001) but a return to 46 +/- 16 mm Hg at follow-up (p less than 0.05). The aortic valve area increased from 0.54 +/- 0.15 to 0.85 +/- 0.23 cm2 after the procedure (p less than 0.0001), but there was a significant decrease to 0.67 +/- 0.19 cm2 at follow-up (p less than 0.05). Of patients free of aortic valve operation or death after 30 days after the procedure, 76% were severely symptomatic before the procedure as compared with 38% at follow-up. In patients undergoing percutaneous aortic balloon valvuloplasty, there is a continued high short-term mortality and a significant incidence of restenosis over short-term follow-up. Nonetheless, a subset of patients do experience sustained clinical improvement from this procedure.